INTERIM REPORT JANUARY - MARCH 2004
INTERIM REPORT JANUARY - MARCH 2004 · Turnover for the first quarter of 2004 amounted to SEK 179.7 (141.3) million, which is an increase of 27 percent. · Operating income amounted to SEK -2.5 (4.7) million, excluding the item affecting comparability for 2003. · Net income after tax amounted to SEK 3.8 (2.8) million, excluding the item affecting comparability for 2003. · Earnings per share amounted to SEK 0.16 (19.20). · RESTYLANE SubQ approved for sales in Europe. · DUROLANE approved for the treatment of osteoarthritis of the hip joint in Europe. · A study on patients with fecal